VYNE Therapeutics Inc.
VYNE
$1.43
-$0.45-23.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -40.00% | -5.56% | 18.97% | 13.20% | -22.59% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -71.85% | -70.55% | -58.18% | -48.00% | 136.59% |
| Change in Net Operating Assets | 8,231.67% | -19.90% | -103.17% | -136.32% | -97.36% |
| Cash from Operations | -34.06% | -20.37% | 0.87% | -8.60% | 13.22% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 140.94% | -1,134.33% | -1,054.28% | -1,441.26% | -466.08% |
| Cash from Investing | 140.74% | -1,134.33% | -1,054.28% | -1,441.26% | -466.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 52,890.38% | 52,890.38% | 52,890.38% | 5,219.27% |
| Repurchase of Common Stock | -110.45% | 83.82% | -19.15% | 54.69% | 41.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | 100.00% | 100.00% | 100.00% | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.17% | 135,598.36% | 206,622.50% | 86,148.96% | 4,884.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3,470.76% | 104.07% | 140.49% | 46.39% | 97.47% |